BALANCE SHEET COMPONENTS

The following table provides the Company's unbilled receivables and deferred revenues from contracts with customers as of December 29, 2017 and September 29, 2017:



(In millions)	December 29, 2017			September 29, 2017
Unbilled receivables - current	$	269.5		$	259.1
Unbilled receivables - long-term ⁽¹⁾	29.0			10.9
Deferred revenues - current	(772.3		)	(755.4		)
Deferred revenues - long-term ⁽²⁾	(8.8		)	(7.2		)
Total net unbilled receivables (deferred revenues)	$	(482.6	)	$	(492.6	)


⁽¹⁾	Included in other assets on the Company's Condensed Consolidated Balance Sheets.


⁽²⁾	Included in other long-term liabilities on the Company's Condensed Consolidated Balance Sheets.

During the three months ended December 29, 2017, unbilled receivables net of deferred revenues increased by $10.0 million primarily due to timing of billings occurring after the revenue was recognized and also milestone payments.

During the three months ended December 29, 2017 and December 30, 2016, the Company recognized revenue of $196.4 million and $218.8 million, respectively, which was included in the deferred revenues balance at September 29, 2017 and September 30, 2016, respectively.

The Company did not have any impairment losses on its unbilled receivables during the three months ended December 29, 2017. The Company recognized an impairment loss of $17.2 million from long-term unbilled receivables during the three months ended December 30, 2016. See Note 15, "VPT Loans and Securities" for further information.

The following table summarizes the Company's inventories:



(In millions)	December 29, 2017		September 29, 2017
Raw materials and parts	$	319.8	$	296.5
Work-in-process	47.6		47.7
Finished goods	64.0		73.5
Total inventories	$	431.4	$	417.7

The following tables summarize the Company's available-for-sale securities:



	December 29, 2017
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
DRTC securities ⁽¹⁾	$	8.0	$	—	$	—	$	8.0
APTC securities ⁽¹⁾	6.0		—		—		6.0
GPTC securities ⁽²⁾	4.5		—		—		4.5
Total available-for-sale securities	$	18.5	$	—	$	—	$	18.5



	September 29, 2017
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Original CPTC loans ⁽²⁾	$	47.4	$	—	$	—	$	47.4
DRTC securities⁽²⁾	8.0		—		—		8.0
GPTC securities ⁽²⁾	4.4		—		—		4.4
Total available-for-sale securities	$	59.8	$	—	$	—	$	59.8


⁽¹⁾	Included in prepaid and other current assets on the Company's Condensed Consolidated Balance Sheets because the Company has the ability and intent to sell these securities in the next twelve months. Subsequent to December 29, 2017, the Company sold its DRTC securities.


⁽²⁾	Included in other assets on the Company's Condensed Consolidated Balance Sheets because the maturity dates are greater than one year and the Company does not have the intent and ability to collect or sell all or a portion of its loans or securities in the next twelve months.

See Note 4, "Fair Value" and Note 15, "VPT Loans and Securities" for more information on the Original California Proton Treatment Center, LLC (“Original CPTC”) Loans, Alabama Proton Therapy Center ("APTC"), Delray Radiation Therapy Center (“DRTC”) and Georgia Proton Treatment Center ("GPTC") Securities.

The following table summarizes the Company's other long-term liabilities:



(In millions)	December 29, 2017		September 29, 2017
Long-term income taxes payable	$	203.0	$	48.6
Deferred income taxes	27.3		17.1
Other	62.1		61.7
Total other long-term liabilities	$	292.4	$	127.4